Continuous Intravascular Glucose Monitoring System achieves CE Mark-GlySure Limited

GlySure Limited has announced that it has secured the CE Mark for the world�s first and only Continuous Intravascular Glucose Monitoring System (CIGMS). The initial use of the GlySure CIGMS is to enhance blood glucose management among adult cardiac surgery patients in the Intensive Care Unit (ICU). The need for enhanced glucose management exists within all critical care settings.

In critically ill patients, poorly controlled blood sugar levels can lead to increased mortality, morbidity, lengths of stay in the ICU and costs to healthcare providers. This CE Mark clears the path for GlySure to market its GlySure CIGMS in Europe. The Company will first bring this solution to leading critical care centres in the UK, Benelux and Germany, followed by launches in additional European countries and other markets where CE Mark is recognised.

Comment: The CE Mark applies specifically for use in intensive care units (ICUs) with adult cardiac surgery patients.